Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors - Wikidata - wikimedia - TriplyDB

Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors

Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors

http://www.wikidata.org/entity/Q28254182

about

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia B-cell survival factors in autoimmune rheumatic disorders Effect of TACI signaling on humoral immunity and autoimmune diseases Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Unbalanced Immune System: Immunodeficiencies and Autoimmunity Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy.Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.Differences in mouse and human nonmemory B cell pools.The function of BAFF on T helper cells in autoimmunity The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF).Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1 The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation.BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Nfkb1 activation by the E26 transformation-specific transcription factors PU.1 and Spi-B promotes Toll-like receptor-mediated splenic B cell proliferation.TACI expression and signaling in chronic lymphocytic leukemia Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells Molecular signature in HCV-positive lymphomas Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival.DNP-KLH Yields Changes in Leukocyte Populations and Immunoglobulin Isotype Use with Different Immunization Routes in Zebrafish.Expression of BAFF and BR3 in patients with systemic lupus erythematosus.Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy B-cell activating factor (BAFF) is elevated in chronic granulomatous disease.CVID-associated TACI mutations affect autoreactive B cell selection and activation.Interferon-driven deletion of antiviral B cells at the onset of chronic infection.IFN type I and II induce BAFF secretion from human decidual stromal cells.Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.Viral-host interaction in kidney reveals strategies to escape host immunity and persistently shed virus to the urine.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date B cells and antibodies in multiple sclerosis pathogenesis and therapy.The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.Is rituximab effective in childhood nephrotic syndrome? Yes and no.Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge.

P2860

Q26784444-84F173ED-7EEA-47FC-BD2A-3BDF0046C994 Q26796484-3F0A695D-12E1-4536-B916-9E7FB5E86534 Q26995571-4CD81A44-5F6F-493C-B4AC-01D95700DF67 Q28066193-30C5EA13-B4B1-45BA-946A-8F7BB6484280 Q28075911-C0717794-5689-40C4-A9EC-33618ABF7B12 Q30245322-9A8C01B6-7905-4259-8573-F396DF751BFA Q33404838-84D61699-9CEC-46F4-932C-BD1B041A7DAB Q33412584-B08CD550-606B-4D32-95C9-5C6A34AB9E47 Q33418352-FC54368B-89FE-411A-BC0D-A8D512EFE4FE Q33716235-0FD42559-9172-4B6A-B583-29A87D4EF35E Q33748041-E0B4C69E-EEED-4201-B36A-94CD7FD325F5 Q33792424-955F88ED-36A1-44B5-85AE-B4232DC93AC2 Q33797482-82A1C4C5-C157-4813-B659-DC1993285FC5 Q34652175-0FED50A9-094A-4454-9866-733AF938F533 Q34656412-80BD2C63-B6B8-4094-88CE-B57FA8AC1406 Q34960458-B7EE2786-931D-4767-BB61-912B4C7137DB Q35288509-386E58CE-DCD6-49F5-BE34-097F245B991F Q35534809-3B285E4C-B6C0-43E3-83D0-E7B621CCBDEA Q35850791-5E0EDAD5-0866-4D41-AAD2-A0770592D40F Q36165173-D613C184-491A-4358-AEFC-01847469738C Q36199986-930CAB52-78FD-4FB9-B79E-C96A03DB3511 Q36253983-45F6D029-75B0-4452-9B0D-B6B9482B6028 Q36271212-659AFD0C-6C91-4C22-BB3C-BE7991EB2195 Q36279914-AF4CBACF-5A69-486F-9FE1-23105BEF096D Q36332734-C9E756D5-83F0-45FD-AF6D-BFE7FEC13ABF Q36607723-229F2B6C-8064-46A5-B55A-7B2846B5544C Q36626153-F2A35780-C142-4871-AF4C-37943C5BEFED Q36722422-C99CE706-CDB7-4837-BDB1-54DD6A3C388C Q37174792-855FF6EC-29A0-43D9-B027-40617200F63A Q37206886-47EF7A12-E38F-489D-88A0-016F3BC0AF9F Q37423183-DB7C10DD-B023-4D26-B53E-C544B78E8C27 Q37563438-7CEBA250-1CC7-4903-8076-50AD03C64F58 Q37700864-B039C2F8-226D-4B8E-92C9-081868A456A7 Q37702518-AE18A5A3-A312-42E9-9F51-9EB65D45349B Q37709763-1C8ED04C-21FA-4213-A467-9BD4BA1C2E17 Q38050398-61B72E09-87DC-45FD-85B2-90A0A9566A24 Q38095861-9D9C33E5-8B92-4EAA-ACDC-8925A35F4701 Q38118894-77F95830-EDE3-4EF6-B4D3-94B61724EFCF Q38187489-BA0B2F2F-F85B-4F31-B6BF-033C531AC416 Q38211700-3A67DA1A-9919-4446-9C22-717635ED25D5

P2860

Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors

http://www.wikidata.org/entity/Q28254182

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@ast

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@en

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@nl

type

label

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@ast

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@en

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@nl

prefLabel

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@ast

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@en

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@nl

P1433

Q28254182-99E8FCF0-EE48-49AF-837C-E227FC086C68

P1476

Q28254182-8FF53FD4-CD33-4B99-BB7B-EB84D6D93737

P2093

Q28254182-0A93A727-90BE-4839-8B77-4DC461AB6D35

Q28254182-575CC24E-F6BA-4530-9D9D-07BB63F4E29A

Q28254182-66641585-4B64-42B2-995B-EF16328D470D

Q28254182-6ECE0377-03CE-45CD-8640-90CF427C0870

Q28254182-7E310570-C7AA-41CD-B8BA-6A019D5846F4

Q28254182-8578E414-E0D4-43A7-B016-BDDBE91880F7

Q28254182-B6136E47-31F4-421F-8598-952F8D7AB5CD

Q28254182-C31B48BB-9D49-4328-863F-F120971AB2BB

Q28254182-D46F28F6-247B-445F-9257-276D20BF7469

Q28254182-D5C9746A-B75E-4162-B25E-95E0DCA199F9

P304

Q28254182-B679BA91-191E-4AD0-BDE9-385F47D5A60A

P31

Q28254182-79FE57D7-5F22-4E44-8941-CF5EF6B7BD98

P3181

Q28254182-403E7586-E070-4D7D-9C00-0D99C4971988

P356

Q28254182-D7309591-6776-4D2C-91CF-A36FEDEB9D2E

P407

Q28254182-4A33836F-8CF6-4F76-9C6D-588267123D9A

P433

Q28254182-1B66BDA8-9B85-4803-997C-F824F8943147

P478

Q28254182-FAE65A36-4B4F-4400-99D0-18E7FD817CBC

P50

Q28254182-696E02F9-65D1-466E-AAAE-A532CC8F4334

P577

Q28254182-23BCFC27-A0B7-46EF-93F2-808A2934829C

P698

Q28254182-84A4C3EC-46F9-4935-8574-F9AB760CC0B1

P3181

P356

JIMMUNOL.1102321

P1433

Journal of Immunology

P1476

Soluble BAFF levels inversely ...... e expression of BAFF receptors

@en

P2093

Alessandro Plebani

http://www.w3.org/2001/XMLSchema#string

Antonius G Rolink

http://www.w3.org/2001/XMLSchema#string

Bodo Grimbacher

http://www.w3.org/2001/XMLSchema#string

Hermann Eibel

http://www.w3.org/2001/XMLSchema#string

Isabella Quinti

http://www.w3.org/2001/XMLSchema#string

Jennifer Birmelin

http://www.w3.org/2001/XMLSchema#string

Jens Thiel

http://www.w3.org/2001/XMLSchema#string

Klaus Warnatz

http://www.w3.org/2001/XMLSchema#string

Marta Rizzi

http://www.w3.org/2001/XMLSchema#string

Matthias Kreuzaler

http://www.w3.org/2001/XMLSchema#string

P304

497-503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

194338

http://www.w3.org/2001/XMLSchema#string

P356

10.4049/JIMMUNOL.1102321

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22124120

http://www.w3.org/2001/XMLSchema#string